Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: A comparison of gadoxetic acid and gadobenate dimeglumine

Antonella Filippone, Anthony Blakeborough, Josy Breuer, Luigi Grazioli, Simone Gschwend, Renate Hammerstingl, Gertraud Heinz-Peer, Thomas Kittner, Andrea Laghi, Edward Leen, Riccardo Lencioni, Olivier Lucidarme, Philipp Remplik, Philip J. Robinson, Stefan G. Ruehm, Fritz Schaefer, Christoforos Stoupis, Bernd Tombach, Pierre Jean Valette, Christoph J. ZechAlexander Huppertz

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Purpose: To compare enhancement of liver parenchyma in MR imaging after injection of hepatocyte-specific contrast media. Materials and Methods: Patients (n = 295) with known/ suspected focal liver lesions randomly received 0.025 mmol gadoxetic acid/kg body weight or 0.05 mmol gadobenate dimeglumine/kg body weight by means of bolus injection. MR imaging was performed before and immediately after injection, and in the delayed phase at approved time points (20 min after injection of gadoxetic acid and 40 min after injection of gadobenate dimeglumine). The relative liver enhancement for the overall population and a cirrhotic subgroup was compared in T1-weighted GRE sequences. An independent radiologist performed signal intensity measurements. Enhancement ratios were compared using confidence intervals (CIs). Results: The relative liver enhancement in the overall population was superior with gadoxetic acid (57.24%) versus gadobenate dimeglumine (32.77%) in the delayed-imaging phase. The enhancement ratio between the contrast media was statistically significant at 1.75 (95% CI: 1.46-2.13). In the delayed phase, the enhancement of cirrhotic liver with gadoxetic acid (57.00%) was comparable to that in the overall population. Enhancement with gadobenate dimeglumine was inferior in cirrhotic liver parenchyma (26.85%). Conclusion: In the delayed, hepatocyte-specific phase, liver enhancement after injection of gadoxetic acid was superior to that obtained with gadobenate dimeglumine.

Original languageEnglish (US)
Pages (from-to)356-364
Number of pages9
JournalJournal of Magnetic Resonance Imaging
Volume31
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Contrast Media
Hepatocytes
Injections
Liver
Body Weight
Confidence Intervals
Population
gadolinium ethoxybenzyl DTPA
gadobenic acid

Keywords

  • Contrast media
  • Gadolinium
  • Hepatocyte-specific magnetic resonance (MR)
  • Imaging
  • Liver cirrhosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media : A comparison of gadoxetic acid and gadobenate dimeglumine. / Filippone, Antonella; Blakeborough, Anthony; Breuer, Josy; Grazioli, Luigi; Gschwend, Simone; Hammerstingl, Renate; Heinz-Peer, Gertraud; Kittner, Thomas; Laghi, Andrea; Leen, Edward; Lencioni, Riccardo; Lucidarme, Olivier; Remplik, Philipp; Robinson, Philip J.; Ruehm, Stefan G.; Schaefer, Fritz; Stoupis, Christoforos; Tombach, Bernd; Valette, Pierre Jean; Zech, Christoph J.; Huppertz, Alexander.

In: Journal of Magnetic Resonance Imaging, Vol. 31, No. 2, 02.2010, p. 356-364.

Research output: Contribution to journalArticle

Filippone, A, Blakeborough, A, Breuer, J, Grazioli, L, Gschwend, S, Hammerstingl, R, Heinz-Peer, G, Kittner, T, Laghi, A, Leen, E, Lencioni, R, Lucidarme, O, Remplik, P, Robinson, PJ, Ruehm, SG, Schaefer, F, Stoupis, C, Tombach, B, Valette, PJ, Zech, CJ & Huppertz, A 2010, 'Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: A comparison of gadoxetic acid and gadobenate dimeglumine', Journal of Magnetic Resonance Imaging, vol. 31, no. 2, pp. 356-364. https://doi.org/10.1002/jmri.22054
Filippone, Antonella ; Blakeborough, Anthony ; Breuer, Josy ; Grazioli, Luigi ; Gschwend, Simone ; Hammerstingl, Renate ; Heinz-Peer, Gertraud ; Kittner, Thomas ; Laghi, Andrea ; Leen, Edward ; Lencioni, Riccardo ; Lucidarme, Olivier ; Remplik, Philipp ; Robinson, Philip J. ; Ruehm, Stefan G. ; Schaefer, Fritz ; Stoupis, Christoforos ; Tombach, Bernd ; Valette, Pierre Jean ; Zech, Christoph J. ; Huppertz, Alexander. / Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media : A comparison of gadoxetic acid and gadobenate dimeglumine. In: Journal of Magnetic Resonance Imaging. 2010 ; Vol. 31, No. 2. pp. 356-364.
@article{39bff0dfc6b34371be952a5f16935e32,
title = "Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: A comparison of gadoxetic acid and gadobenate dimeglumine",
abstract = "Purpose: To compare enhancement of liver parenchyma in MR imaging after injection of hepatocyte-specific contrast media. Materials and Methods: Patients (n = 295) with known/ suspected focal liver lesions randomly received 0.025 mmol gadoxetic acid/kg body weight or 0.05 mmol gadobenate dimeglumine/kg body weight by means of bolus injection. MR imaging was performed before and immediately after injection, and in the delayed phase at approved time points (20 min after injection of gadoxetic acid and 40 min after injection of gadobenate dimeglumine). The relative liver enhancement for the overall population and a cirrhotic subgroup was compared in T1-weighted GRE sequences. An independent radiologist performed signal intensity measurements. Enhancement ratios were compared using confidence intervals (CIs). Results: The relative liver enhancement in the overall population was superior with gadoxetic acid (57.24{\%}) versus gadobenate dimeglumine (32.77{\%}) in the delayed-imaging phase. The enhancement ratio between the contrast media was statistically significant at 1.75 (95{\%} CI: 1.46-2.13). In the delayed phase, the enhancement of cirrhotic liver with gadoxetic acid (57.00{\%}) was comparable to that in the overall population. Enhancement with gadobenate dimeglumine was inferior in cirrhotic liver parenchyma (26.85{\%}). Conclusion: In the delayed, hepatocyte-specific phase, liver enhancement after injection of gadoxetic acid was superior to that obtained with gadobenate dimeglumine.",
keywords = "Contrast media, Gadolinium, Hepatocyte-specific magnetic resonance (MR), Imaging, Liver cirrhosis",
author = "Antonella Filippone and Anthony Blakeborough and Josy Breuer and Luigi Grazioli and Simone Gschwend and Renate Hammerstingl and Gertraud Heinz-Peer and Thomas Kittner and Andrea Laghi and Edward Leen and Riccardo Lencioni and Olivier Lucidarme and Philipp Remplik and Robinson, {Philip J.} and Ruehm, {Stefan G.} and Fritz Schaefer and Christoforos Stoupis and Bernd Tombach and Valette, {Pierre Jean} and Zech, {Christoph J.} and Alexander Huppertz",
year = "2010",
month = "2",
doi = "10.1002/jmri.22054",
language = "English (US)",
volume = "31",
pages = "356--364",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media

T2 - A comparison of gadoxetic acid and gadobenate dimeglumine

AU - Filippone, Antonella

AU - Blakeborough, Anthony

AU - Breuer, Josy

AU - Grazioli, Luigi

AU - Gschwend, Simone

AU - Hammerstingl, Renate

AU - Heinz-Peer, Gertraud

AU - Kittner, Thomas

AU - Laghi, Andrea

AU - Leen, Edward

AU - Lencioni, Riccardo

AU - Lucidarme, Olivier

AU - Remplik, Philipp

AU - Robinson, Philip J.

AU - Ruehm, Stefan G.

AU - Schaefer, Fritz

AU - Stoupis, Christoforos

AU - Tombach, Bernd

AU - Valette, Pierre Jean

AU - Zech, Christoph J.

AU - Huppertz, Alexander

PY - 2010/2

Y1 - 2010/2

N2 - Purpose: To compare enhancement of liver parenchyma in MR imaging after injection of hepatocyte-specific contrast media. Materials and Methods: Patients (n = 295) with known/ suspected focal liver lesions randomly received 0.025 mmol gadoxetic acid/kg body weight or 0.05 mmol gadobenate dimeglumine/kg body weight by means of bolus injection. MR imaging was performed before and immediately after injection, and in the delayed phase at approved time points (20 min after injection of gadoxetic acid and 40 min after injection of gadobenate dimeglumine). The relative liver enhancement for the overall population and a cirrhotic subgroup was compared in T1-weighted GRE sequences. An independent radiologist performed signal intensity measurements. Enhancement ratios were compared using confidence intervals (CIs). Results: The relative liver enhancement in the overall population was superior with gadoxetic acid (57.24%) versus gadobenate dimeglumine (32.77%) in the delayed-imaging phase. The enhancement ratio between the contrast media was statistically significant at 1.75 (95% CI: 1.46-2.13). In the delayed phase, the enhancement of cirrhotic liver with gadoxetic acid (57.00%) was comparable to that in the overall population. Enhancement with gadobenate dimeglumine was inferior in cirrhotic liver parenchyma (26.85%). Conclusion: In the delayed, hepatocyte-specific phase, liver enhancement after injection of gadoxetic acid was superior to that obtained with gadobenate dimeglumine.

AB - Purpose: To compare enhancement of liver parenchyma in MR imaging after injection of hepatocyte-specific contrast media. Materials and Methods: Patients (n = 295) with known/ suspected focal liver lesions randomly received 0.025 mmol gadoxetic acid/kg body weight or 0.05 mmol gadobenate dimeglumine/kg body weight by means of bolus injection. MR imaging was performed before and immediately after injection, and in the delayed phase at approved time points (20 min after injection of gadoxetic acid and 40 min after injection of gadobenate dimeglumine). The relative liver enhancement for the overall population and a cirrhotic subgroup was compared in T1-weighted GRE sequences. An independent radiologist performed signal intensity measurements. Enhancement ratios were compared using confidence intervals (CIs). Results: The relative liver enhancement in the overall population was superior with gadoxetic acid (57.24%) versus gadobenate dimeglumine (32.77%) in the delayed-imaging phase. The enhancement ratio between the contrast media was statistically significant at 1.75 (95% CI: 1.46-2.13). In the delayed phase, the enhancement of cirrhotic liver with gadoxetic acid (57.00%) was comparable to that in the overall population. Enhancement with gadobenate dimeglumine was inferior in cirrhotic liver parenchyma (26.85%). Conclusion: In the delayed, hepatocyte-specific phase, liver enhancement after injection of gadoxetic acid was superior to that obtained with gadobenate dimeglumine.

KW - Contrast media

KW - Gadolinium

KW - Hepatocyte-specific magnetic resonance (MR)

KW - Imaging

KW - Liver cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=75749105062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749105062&partnerID=8YFLogxK

U2 - 10.1002/jmri.22054

DO - 10.1002/jmri.22054

M3 - Article

C2 - 20099349

AN - SCOPUS:75749105062

VL - 31

SP - 356

EP - 364

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 2

ER -